Shift work and subclinical atherosclerosis: Recommendations for fatty liver disease detection

Abstract

Proper screening for cardiovascular risk and fatty liver disease will be critical in primary prevention and in the treatment of existing but undiagnosed cardiovascular and liver disease in young individuals. Accordingly, NAFLD may contribute to the systemic inflammation and insulin resistance, which are critical events in the pathophysiology of the cardiometabolic syndrome. In such cases, type II angiotensin receptor blockers are promising therapeutics agents.